Volume 7.05 | Feb 9

Newsletter Issue
Hematopoiesis News 7.05 February 9, 2016
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HN on Twitter
 
TOP STORY
Scientists Discover a Unique Mechanism for a High-Risk Leukemia
Researchers discovered details of how the abnormal breakage and rearrangement of chromosomes in white blood cells triggers a particularly aggressive form of acute lymphoblastic leukemia. Genomic analysis revealed the details of four distinctly different chromosomal rearrangements in the leukemia. All resulted in a truncated version of a gene called the erythropoietin receptor gene, and all produced the same outcome—driving the white blood cells to proliferate out of control. [Press release from St. Jude Children’s Research Hospital discussing online prepublication in Cancer Cell] Press Release | Abstract | Graphical Abstract
Learn more about T cell activation and expansion with ImmunoCult™
 
PUBLICATIONS (Ranked by impact factor of the journal)
Functional and Molecular Characterization of Mouse Gata2-Independent Hematopoietic Progenitors
Scientists generated a Gata2Venus reporter mouse model with unperturbed Gata2 expression to examine the hematopoietic function and transcriptome of Gata2 expressing and non-expressing cells. [Blood] Abstract

BCOR Regulates Myeloid Cell Proliferation and Differentiation
Investigators explored the function of BCOR in myeloid cells using myeloid murine models with Bcor conditional loss-of-function or overexpression alleles. Bcor mutant bone marrow cells showed significantly higher proliferation and differentiation rates with upregulated expression of Hox genes. [Leukemia] Abstract

Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes
Researchers investigated the consequences of inhibiting lysine specific demethylase 1 (KDM1A) in a panel of cell lines representing all acute myeloid leukemia subtypes using selective, reversible and irreversible KDM1A small molecule inhibitors. [Cancer Res] Abstract

The Slicer Endonuclease Argonaute 2 is a Negative Regulator of Hematopoietic Stem Cell Quiescence
To identify the functions of the slicer endonuclease Argonaute (Ago) 2 in the physiology of hematopoietic stem cells (HSCs), scientists generated Ago2Hem-KO mice, that are deficient for Ago2 in HSCs and in their progeny. [Stem Cells] Abstract

FYN Expression Potentiates FLT3-ITD Induced STAT5 Signaling in Acute Myeloid Leukemia
The authors studied the role of FYN in FLT3 signaling in respect to acute myeloid leukemia. They observed that FYN displays a strong association with wild-type FLT3 as well as oncogenic FLT3-ITD and is dependent on the kinase activity of FLT3 and the SH2 domain of FYN. [Oncotarget] Full Article

miR-203 Inhibits Proliferation and Self-Renewal of Leukemia Stem Cells by Targeting Survivin and Bmi-1
Investigators found that miR-203 expression was down-regulated in CD34+ AML cells as compared with CD34 cells isolated from patients as well as in leukemia stem cells-enriched (CD34+ CD38) cell lines KG-1a or MOLM13. [Sci Rep] Full Article

Depletion of SAM50 Specifically Targets BCR-ABL-Expressing Leukemic Stem and Progenitor Cells by Interfering with Mitochondrial Functions
Scientists observed that human leukemic cells display a specific dependency on SAM50 expression, as downregulation of SAM50 in BCR-ABL-expressing, but not normal CD34+ human hematopoietic stem and progenitor cells caused a significant decrease in growth, colony formation, and replating capacity. [Stem Cells Dev] Abstract

CLINICAL RESEARCH

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Non-Transformed Follicular Lymphomas
The authors identified subgroups of follicular lymphoma (FL) patients who benefit from hematopoietic cell transplantation (HCT). HCT for FL was associated with acceptable non-relapse mortality, and offers a substantial chance of cure for patients with refractory disease or advanced age. [Bone Marrow Transplant] Abstract

A Reduced Intensity Conditioning Regimen for Patients with Dyskeratosis Congenita Undergoing Hematopoietic Stem Cell Transplantation
Researchers report their experience in seven patients with dyskeratosis congenita who underwent allogeneic transplant using a reduced intensity conditioning preparative regimen that contained chemotherapy only. [Biol Blood Marrow Transplant] Abstract

It all starts with the right cells! Order fresh and frozen primary cells now.
 
REVIEWS
Therapeutically Targeting Self-Reinforcing Leukemic Niches in Acute Myeloid Leukemia (AML): A Worthy Endeavour?
A tight relationship between the acute myeloid leukemia (AML) population and the bone marrow (BM) microenvironment has been convincingly established. The AML clone contains leukemic stem cells that compete with normal hematopoietic stem cells (HSCs) for niche occupancy and remodel the niche; whereas, the BM microenvironment might promote AML development and progression not only through hypoxia and homing/adhesion molecules, but also through genetic defects. [Am J Hematol] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
 
INDUSTRY NEWS
With $3 Million Award, HSU Generates Stem Cell Scholars
Humboldt State University (HSU) biology professors Jacob Varkey and Amy Sprowles are among educators at 12 universities to secure funding from the California Institute for Regenerative Medicine’s Bridges 2.0 Training Program. The award of $3,044,950 will fund stem cell training for HSU students and support up to ten paid research internships annually for the next five years. [Humboldt State University] Press Release

Terry Fox Award Helps Ottawa Researcher Develop Next-Generation Cancer Immunovirotherapy
The Terry Fox Research Institute has awarded Dr. Guy Ungerechts (The Ottawa Hospital and the University of Ottawa) a $450,000 New Investigator grant to develop innovative new treatments to destroy cancer cells and stimulate a patient’s own immune system to attack tumors, while leaving healthy tissues unharmed. [Terry Fox Research Institute] Press Release

ADC Therapeutics Doses First Patient in Phase I Trial of ADCT-301 Trial in Acute Myeloid Leukemia
ADC Therapeutics SA (ADCT) announced that the first patient has been dosed in a Phase I trial to evaluate its lead antibody drug conjugate (ADC) ADCT-301 in Acute Myeloid Leukemia. [ADC Therapeutics SA (Business Wire)] Press Release

From our sponsor: Isolate human immune cells in as little as 8 minutes with EasySep™ Request a sample.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Malaysian Association for Cell Therapy (MACT) 2016 Scientific Symposium
April 2-2, 2016
Kuala Lumpur, Malaysia

Visit our events page to see a complete list of events in the hematopoiesis community.
 
JOB OPPORTUNITIES
NEW Translational Research Scientist – Hematology/Oncology (University of Chicago)

Postdoctoral Associate – Epigenetic Regulation of Normal and Leukemic Stem Cells (Sanford Burnham Prebys Medical Discovery Institute)

Postdoctoral Researcher – Pre-Leukemic Stem Cells in the Thymus (Ghent University)

Laboratory Technician – Molecular Biology (Icahn School of Medicine at Mount Sinai)

Postdoctoral Fellow – Stem Cell Biology (Krembil Research Institute)

Postdoctoral Scholarship – Cancer Biology (Lund University)

Postdoctoral Fellowship – Tumor Immunology and Cancer Metabolism (Yale University)

Postdoctoral Fellow – Leukemia Biology (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Epigenetics and RNA Splicing (National Cancer Institute)

Assistant/Associate/Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us